Jorge Nieva, MD

Articles

Dr Nieva on the Rationale for Investigating At-Home Atezolizumab Administration in NSCLC

November 1st 2023

Jorge Nieva, MD, discusses the rationale and design of an ongoing phase 2 trial investigating a telemedicine approach to delivering subcutaneous atezolizumab for patients with non–small cell lung cancer.

Takeaways and Considerations for the Future in the Treatment of SCLC

July 5th 2023

Jorge Nieva, MD, and Ashish Saxena, MD, PhD, discuss the possibility of expanding the use of supportive care regimens to reduce the effects of myelosuppression in patients with SCLC.

Practical Considerations Regarding the Incorporation of Supportive Care Into Practice

June 28th 2023

Jorge Nieva, MD, and Ashish Saxena, MD, PhD, consider the broader impact of supportive care on cost burden and quality of life and share scenarios in which supportive care is most appropriate.

Quality of Life and Patient-Reported Outcome Measures in SCLC Treatment

June 28th 2023

Jorge Nieva, MD, and Ashish Saxena, MD, PhD, share insights about the value of patient-reported outcomes studies and the extent to which they can shape treatment decisions.

The Role of Supportive Care in the Management of Myelosuppression in Patients With SCLC

June 21st 2023

Jorge Nieva, MD, and Ashish Saxena, MD, PhD, talk about factors to consider when weighing the risk/benefit ratio associated with the use of cyclin-dependent kinase 4/6 inhibition.

Challenges in the Management of Patients With SCLC

June 21st 2023

Jorge Nieva, MD, and Ashish Saxena, MD, PhD, discuss the impact of chemotherapy-induced myelosuppression on patients with SCLC.